NCT00723047

Brief Summary

This multicenter, randomized, controlled trial was conducted by the Groupe d'Etude Thérapeutique des Affections Inflammatoires du tube Digestif (GETAID) to evaluate the efficacy and safety of the injection of fibrin glue in perianal fistulas tracts of patients with CD. The institutional Independent Ethics Committee of Marseille, France and of Liège, Belgium approved the protocol for each participating centers. Recruitment took place at 12 sites (11 in France and 1 in Belgium)

Trial Health

90
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
77

participants targeted

Target at below P25 for phase_3

Timeline
Completed

Started Nov 2003

Typical duration for phase_3

Geographic Reach
2 countries

14 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2003

Completed
2.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2006

Completed
2 months until next milestone

Study Completion

Last participant's last visit for all outcomes

August 1, 2006

Completed
2 years until next milestone

First Submitted

Initial submission to the registry

July 25, 2008

Completed
3 days until next milestone

First Posted

Study publicly available on registry

July 28, 2008

Completed
Last Updated

September 5, 2011

Status Verified

September 1, 2011

Enrollment Period

2.6 years

First QC Date

July 25, 2008

Last Update Submit

September 2, 2011

Conditions

Keywords

PatientsCD complicatedleastOne perianal fistulaDraining2 months duration

Outcome Measures

Primary Outcomes (1)

  • Clinical Remission

    Clinical remission was defined as * the absence of any draining by fistula openings occurring spontaneously or after gentle finger compression , * the absence of perianal pain * and the absence of perianal abscess.

    8 weeks after inclusion

Secondary Outcomes (2)

  • Early Clinical Remission

    4 weeks after Inclusion

  • Occurrence of perianal abcess

    During whole study

Study Arms (1)

1

EXPERIMENTAL
Procedure: Fibrin glue injection in fistula

Interventions

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • at least 18 years old
  • CD confirmed by endoscopy and histology.
  • CDAI should be 250 or less
  • at least one perianal fistula (between anus or low rectum and perineum, vulva or vagina) draining for more than 2 months duration

You may not qualify if:

  • treatment with an anti-TNF agent or with ciclosporin or tacrolimus within the last 3 months
  • presence of a perianal abscess (\>1cm) assessed by magnetic resonance imaging (MRI) or endo-anal ultrasonography performed within the last month,
  • presence of anal or rectal stenosis,
  • surgery during the previous month (except seton removal),
  • previous fibrin glue injection,
  • pregnancy.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (14)

Sart Tilman University Hospital

Liège, 4000, Belgium

Location

Beaujon Hospital

Clichy, 92110, France

Location

Louis Mourrier Hospital

Colombes, 92700, France

Location

CHRU Lille

Lille, France

Location

Marseille North Hospital

Marseille, 13915, France

Location

Nice University Hospital

Nice, 06202, France

Location

Hopital St Louis

Paris, 75010, France

Location

Lariboisiere Hospital

Paris, 75010, France

Location

Georges Pompidou European Hospital

Paris, 75015, France

Location

Bichat Hospital

Paris, 75018, France

Location

Lyon Sud University Hospital

Pierre-Bénite, 69495, France

Location

Pontchaillou University Hospital

Rennes, 35033, France

Location

Rouen University Hospital

Rouen, 76031, France

Location

Trousseau University Hospital

Tours, 37044, France

Location

Related Publications (7)

  • Hellers G, Bergstrand O, Ewerth S, Holmstrom B. Occurrence and outcome after primary treatment of anal fistulae in Crohn's disease. Gut. 1980 Jun;21(6):525-7. doi: 10.1136/gut.21.6.525.

    PMID: 7429313BACKGROUND
  • Schwartz DA, Loftus EV Jr, Tremaine WJ, Panaccione R, Harmsen WS, Zinsmeister AR, Sandborn WJ. The natural history of fistulizing Crohn's disease in Olmsted County, Minnesota. Gastroenterology. 2002 Apr;122(4):875-80. doi: 10.1053/gast.2002.32362.

    PMID: 11910338BACKGROUND
  • Schwartz DA, Pemberton JH, Sandborn WJ. Diagnosis and treatment of perianal fistulas in Crohn disease. Ann Intern Med. 2001 Nov 20;135(10):906-18. doi: 10.7326/0003-4819-135-10-200111200-00011.

    PMID: 11712881BACKGROUND
  • Bernstein LH, Frank MS, Brandt LJ, Boley SJ. Healing of perineal Crohn's disease with metronidazole. Gastroenterology. 1980 Aug;79(2):357-65.

    PMID: 7399243BACKGROUND
  • Present DH, Korelitz BI, Wisch N, Glass JL, Sachar DB, Pasternack BS. Treatment of Crohn's disease with 6-mercaptopurine. A long-term, randomized, double-blind study. N Engl J Med. 1980 May 1;302(18):981-7. doi: 10.1056/NEJM198005013021801.

    PMID: 6102739BACKGROUND
  • Pearson DC, May GR, Fick GH, Sutherland LR. Azathioprine and 6-mercaptopurine in Crohn disease. A meta-analysis. Ann Intern Med. 1995 Jul 15;123(2):132-42. doi: 10.7326/0003-4819-123-2-199507150-00009.

    PMID: 7778826BACKGROUND
  • Grimaud JC, Munoz-Bongrand N, Siproudhis L, Abramowitz L, Senejoux A, Vitton V, Gambiez L, Flourie B, Hebuterne X, Louis E, Coffin B, De Parades V, Savoye G, Soule JC, Bouhnik Y, Colombel JF, Contou JF, Francois Y, Mary JY, Lemann M; Groupe d'Etude Therapeutique des Affections Inflammatoires du Tube Digestif. Fibrin glue is effective healing perianal fistulas in patients with Crohn's disease. Gastroenterology. 2010 Jun;138(7):2275-81, 2281.e1. doi: 10.1053/j.gastro.2010.02.013. Epub 2010 Feb 20.

Related Links

MeSH Terms

Conditions

Crohn Disease

Interventions

Fibrin Tissue Adhesive

Condition Hierarchy (Ancestors)

Inflammatory Bowel DiseasesGastroenteritisGastrointestinal DiseasesDigestive System DiseasesIntestinal Diseases

Intervention Hierarchy (Ancestors)

FibrinBlood ProteinsProteinsAmino Acids, Peptides, and Proteins

Study Design

Study Type
interventional
Phase
phase 3
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
CROSSOVER
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

July 25, 2008

First Posted

July 28, 2008

Study Start

November 1, 2003

Primary Completion

June 1, 2006

Study Completion

August 1, 2006

Last Updated

September 5, 2011

Record last verified: 2011-09

Locations